KMT2A and acute myeloid leukemia: We next determined the in vivo anti-leukemia efficacy of SNDX-50469 or SNDX-5613 and/or OTX015 in an aggressive and lethal MOLM13 xenograft model or in an AML PDX (PD xenograft) model expressing MLL-AF9 and FLT3-TKD, both models transduced with Luciferase/GFP for bioluminescence imaging.